IDEXX LABORATORIES INC /DE
In Vitro & In Vivo Diagnostic Substances
Computed from SEC EDGAR filings and closing prices — not copied from any wealth ranking. Dataset . How we calculate this.
What IDEXX LABORATORIES INC /DE reports
Revenue and net income below are for fiscal period FY2025, the period label carried by this company’s own annual XBRL filings to the SEC. Fiscal years do not line up between companies — one company’s FY2026 can cover much the same months as another’s FY2025 — so compare the periods, not just the numbers.
Where the employee count comes from
Headcount comes from Yahoo Finance, not from a filing. The date beside it is the day we retrieved the figure — it is not the date the company counted its staff, and Yahoo does not publish that date. Unlike the SEC filings behind the other figures on this page, this one carries no open licence, so we publish the number and nothing else from that source.
Insiders at IDEXX LABORATORIES INC /DE
Shares is what each person last reported holding here.
Everyone below has filed at least one insider report against this company.
Value is that share count priced at the same closing price used everywhere else on this site. A row priced from only some of a person’s securities says so — we do not quietly present a partial sum as a complete one.
Rows are grouped by the role each person reports.
The role comes from the relationship boxes a person ticks on their own insider filings — officer, director, ten per cent owner — not from anything we infer. Somebody who is both an officer and a director appears once, in the combined group, so the row count still matches the figure at the top of this page. Where no filing states a role we say so instead of guessing one.
| Insider | Reported role | Shares | Value | Last action |
|---|---|---|---|---|
| Officers 8 | ||||
| Michael G Erickson | EVP | 15,092 | $8.08M | M Option exercise or conversion Feb 19, 2026 position reported |
George Fennell
|
EVP | 10,078 | $5.40M | F Shares withheld for taxes Jun 1, 2026 position reported |
Michael Lane
|
EVP | 8,616 | $4.61M | M Option exercise or conversion Feb 14, 2026 position reported |
Sharon E Underberg
|
General Counsel | 7,138 | $3.82M | M Option exercise or conversion Mar 3, 2026 position reported |
Andrew Emerson
|
CFO | 4,222 | $2.26M | F Shares withheld for taxes Aug 20, 2026 position reported |
Michael Schreck
|
EVP | 3,089 | $1.65M | M Option exercise or conversion Feb 14, 2026 position reported |
Michael Perkins Johnson
|
EVP | 2,795 | $1.50M | F Shares withheld for taxes Feb 14, 2026 position reported |
Martin Alexander Smith
|
EVP | 2,157 | $1.15M | M Option exercise or conversion Feb 14, 2026 position reported |
| Officers who also sit on the board 4 | ||||
Jonathan Jay Mazelsky
|
CEO | 83,803 | $44.87M | M Option exercise or conversion Feb 27, 2026 position reported |
| Brian P. McKeon | CFO | 49,600 | $26.55M | — position reported |
| Nimrata Hunt | EVP | 18,301 | $9.80M | S Open-market sale Mar 3, 2026 position reported |
Stuart Essig
|
Executive Chairman | 2,236 | $1.20M | M Option exercise or conversion May 6, 2025 position reported |
| Directors 8 | ||||
| Jonathan W. Ayers | Board Member | 577,830 | $309.36M | — position reported |
Lawrence D Kingsley
|
Board Member | 9,229 | $4.94M | S Open-market sale Sep 4, 2026 position reported |
| Sophie V Vandebroek | Board Member | 8,821 | $4.72M | M Option exercise or conversion May 7, 2026 position reported |
| Daniel M. Junius | Board Member | 3,304 | $1.77M | M Option exercise or conversion May 7, 2026 position reported |
| M. Anne Szostak | Board Member | 2,970 | $1.59M | M Option exercise or conversion May 7, 2026 position reported |
| Bruce L Claflin | Board Member | 1,721 | $921.4K | — position reported |
| Irene Chang Britt | Board Member | 208 | $111.4K | — position reported |
| Joseph L. Hooley | Board Member | 75 | $40.2K | A Grant or award Jul 30, 2026 position reported |
Recent insider transactions
Of the 255 rows we hold, 0 are open-market purchases and 66 open-market sales (S) — the only codes we count as buying or selling.
The rest — awards, shares withheld to pay tax, option exercises, gifts and so on — follow from an employment contract or a transfer arranged off-market, not from a decision to buy or sell, so counting them would turn this into a pay table.
A price of 0.00 is a real reported figure on gifts (G) and share awards (A) — not a gap in our data.
| Date | Insider | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 4, 2026 | Lawrence D Kingsley | S Open-market sale | 2,203 | $532.08 | $1.17M | SEC filing ↗ |
| Sep 4, 2026 | Lawrence D Kingsley | M Option exercise or conversion | 2,203 | $114.17 | $251.5K | SEC filing ↗ |
| Aug 20, 2026 | Andrew Emerson | F Shares withheld for taxes | 86 | $0.00 | $0 | SEC filing ↗ |
| Aug 20, 2026 | Andrew Emerson | M Option exercise or conversion | 265 | $178.26 | $47.2K | SEC filing ↗ |
| Jul 30, 2026 | Joseph L. Hooley | A Grant or award | 49 | $558.80 | $27.4K | SEC filing ↗ |
| Jun 1, 2026 | George Fennell | F Shares withheld for taxes | 284 | $566.79 | $161.0K | SEC filing ↗ |
| Jun 1, 2026 | George Fennell | M Option exercise or conversion | 639 | $0.00 | $0 | SEC filing ↗ |
| May 7, 2026 | Sophie V Vandebroek | M Option exercise or conversion | 257 | $0.00 | $0 | SEC filing ↗ |
| May 7, 2026 | M. Anne Szostak | M Option exercise or conversion | 257 | $0.00 | $0 | SEC filing ↗ |
| May 7, 2026 | Lawrence D Kingsley | M Option exercise or conversion | 82 | $0.00 | $0 | SEC filing ↗ |
| May 7, 2026 | Lawrence D Kingsley | M Option exercise or conversion | 257 | $0.00 | $0 | SEC filing ↗ |
| May 7, 2026 | Daniel M. Junius | M Option exercise or conversion | 257 | $0.00 | $0 | SEC filing ↗ |
| May 7, 2026 | Joseph L. Hooley | M Option exercise or conversion | 158 | $0.00 | $0 | SEC filing ↗ |
| Apr 30, 2026 | Joseph L. Hooley | A Grant or award | 43 | $560.80 | $24.1K | SEC filing ↗ |
| Mar 3, 2026 | Nimrata Hunt | S Open-market sale | 1,758 | $634.57 | $1.12M | SEC filing ↗ |
| Mar 3, 2026 | Sharon E Underberg | M Option exercise or conversion | 197 | $505.53 | $99.6K | SEC filing ↗ |
| Feb 27, 2026 | Jonathan Jay Mazelsky | M Option exercise or conversion | 197 | $505.53 | $99.6K | SEC filing ↗ |
| Feb 26, 2026 | Nimrata Hunt | S Open-market sale | 2,693 | $661.54 | $1.78M | SEC filing ↗ |
| Feb 26, 2026 | Jonathan Jay Mazelsky | S Open-market sale | 3,660 | $658.92 | $2.41M | SEC filing ↗ |
| Feb 26, 2026 | Jonathan Jay Mazelsky | S Open-market sale | 1,343 | $656.85 | $882.1K | SEC filing ↗ |
| Feb 26, 2026 | Jonathan Jay Mazelsky | S Open-market sale | 1,488 | $655.85 | $975.9K | SEC filing ↗ |
| Feb 26, 2026 | Jonathan Jay Mazelsky | S Open-market sale | 1,111 | $654.63 | $727.3K | SEC filing ↗ |
| Feb 26, 2026 | Jonathan Jay Mazelsky | S Open-market sale | 1,171 | $653.68 | $765.5K | SEC filing ↗ |
| Feb 26, 2026 | Jonathan Jay Mazelsky | S Open-market sale | 1,669 | $652.49 | $1.09M | SEC filing ↗ |
| Feb 26, 2026 | Jonathan Jay Mazelsky | S Open-market sale | 2,859 | $659.75 | $1.89M | SEC filing ↗ |
From SEC Form 4 filings. Every row links to the filing it came from. How we calculate this.
What a Form 4 is
The report an officer, director or large shareholder must file after trading their own company’s stock.
Subsidiaries — 59 legal entities
Subsidiaries of IDEXX LABORATORIES INC /DE
59 legal entities named in the subsidiary exhibit filed with this company’s most recent 10-K. . Filing on SEC.gov.
This is not the full list. SEC rules only require a company to name its significant subsidiaries.
What that leaves out
Smaller entities are left out of the exhibit entirely. A short list here means a short exhibit — it does not mean the company owns nothing else. Nothing on this page is inferred: every name below is copied from the filing.
| Subsidiary | Organised in |
|---|---|
| 342 Saco Street, LLC | Maine |
| Beijing IDEXX Laboratories Co. Limited | China |
| IDEXX Animana B.V. | Netherlands |
| IDEXX B.V. | Netherlands |
| IDEXX Brasil Laboratórios Ltda. | Brazil |
| IDEXX Brasil Participações Ltda. | Brazil |
| IDEXX Canada Holdings Corp. | Delaware |
| IDEXX Diagnostic Limited | Ireland |
| IDEXX Diavet AG | Schwyz |
| IDEXX Distribution, Inc. | Massachusetts |
| IDEXX GmbH | Germany |
| IDEXX Holding GmbH | Germany |
| IDEXX Holdings GmbH | Zug |
| IDEXX Holdings II GmbH | Zug |
| IDEXX Holdings, Inc. | Delaware |
| IDEXX Laboratories (Proprietary) Limited | South Africa |
| IDEXX Laboratories (Shanghai) Company Limited | China |
| IDEXX Laboratories B.V. | Netherlands |
| IDEXX Laboratories Canada 1, ULC | Nova Scotia |
| IDEXX Laboratories Canada Corporation | Nova Scotia |
| IDEXX Laboratories Co., Ltd. | Thailand |
| IDEXX Laboratories Danmark ApS | Denmark |
| IDEXX Laboratories GmbH | Zug |
| IDEXX Laboratories Hong Kong Limited | Hong Kong |
| IDEXX Laboratories II (NZ) ULC | New Zealand |
| IDEXX Laboratories Italia S.r.l. | Italy |
| IDEXX Laboratories Limited | England & Wales |
| IDEXX Laboratories Ltd. | Korea, Republic of |
| IDEXX Laboratories Norge AS | Norway |
| IDEXX Laboratories Oy | Finland |
| IDEXX Laboratories Philippines, Inc. | Philippines |
| IDEXX Laboratories Private Limited | India |
| IDEXX Laboratories Pty Limited | New South Wales |
| IDEXX Laboratories s.r.o. | Czech Republic |
| IDEXX Laboratories Singapore Pte. Ltd. | Singapore |
| IDEXX Laboratories Slovakia s.r.o. | Slovak Republic |
| IDEXX Laboratories Sp. z o.o. | Poland |
| IDEXX Laboratories SRL | Belgium |
| IDEXX Laboratories Sverige AB | Sweden |
| IDEXX LABORATORIES, INC. | — |
| IDEXX Laboratories, KK | Japan |
| IDEXX Laboratories, S.de R.L. de C.V. | Mexico |
| IDEXX Laboratorios, S.L. | Spain |
| IDEXX Montpellier SAS | France |
| IDEXX Operations, Inc. | Delaware |
| IDEXX Pharmaceuticals, LLC | Delaware |
| IDEXX Real Estate Holdings GmbH | Germany |
| IDEXX Real Estate Holdings, LLC | Maine |
| IDEXX SARL | France |
| IDEXX Switzerland GmbH | Bern/Berne |
| IDEXX Technologies GmbH | Bern/Berne |
| IDEXX Technologies Limited | England & Wales |
| IDEXX UK Acquisition Limited | England & Wales |
| IDEXX Vet Med Labor GmbH | Austria |
| IDEXXLAB, Unipessoal Lda. | Portugal |
| labor-zentral.ch AG für veterinärmedizinische Diagnostik | Lucerne |
| Laboratoire IDEXX SARL | France |
| OPTI Medical Systems, Inc. | Delaware |
| Vet Med Labor GmbH | Germany |
What counts as a subsidiary
A subsidiary is a separate legal entity this company controls; it is not the same thing as a brand, a division or an office. These entities do not file with the SEC in their own right, so there is no separate page to open for them.
Think a number here is wrong? Open the linked filing and compare — how to report it.
Sources and technical notes
Every figure on this page comes from filings to the U.S. SEC via EDGAR. Nothing here is estimated, and nothing is taken from press coverage or company websites.
Share count: cover page of the latest filing (dei:EntityCommonStockSharesOutstanding), taken from
IDEXX LABORATORIES INC /DE’s own filings and multiplied by our closing price.
Full method.
What that share count means
the share count the company itself prints on the cover of its most recent filing, as of the date it signed that filing.
We do not take a market cap from a data vendor, and we do not estimate one: the figure is a share count from IDEXX LABORATORIES INC /DE’s own SEC filings multiplied by the closing price we hold for the same stock.
Logo: http://www.idexx.com/ / Public domain , via Wikimedia Commons ↗ — used here to identify the company. Trademarks remain the property of their owner.